Avenue Therapeutics Inc (ATXI) USD0.0001

Sell:$0.77Buy:$0.77$0.07 (7.86%)

Prices delayed by at least 15 minutes
Sell:$0.77
Buy:$0.77
Change:$0.07 (7.86%)
Deal now
Prices delayed by at least 15 minutes
Sell:$0.77
Buy:$0.77
Change:$0.07 (7.86%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Avenue Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201 for the treatment of spinal and bulbar muscular atrophy (SBMA, also known as Kennedy's Disease), intravenous tramadol (IV tramadol) for the treatment of post-operative acute pain, and BAER-101 for the treatment of epilepsy and panic disorders. AJ201 is designed to modify SBMA through multiple mechanisms, including degradation of the mutant androgen receptor (AR) protein and stimulation of the Nrf1 and Nrf2 pathways, which are involved in protecting cells from oxidative stress that can lead to cell death. Baergic’s pipeline consists of a single compound, BAER-101, a novel α2/3 subtype-selective GABA A positive allosteric modulator.

Key people

Alexandra Maclean
Chief Executive Officer, Director
David Jin
Interim Chief Financial Officer, Chief Operating Officer
Jay D. Kranzler
Non-Executive Chairman of the Board
Lindsay A. Rosenwald
Director
Faith L. Charles
Independent Director
Neil Herskowitz
Independent Director
Curtis Gale Oltmans
Independent Director
Click to see more

Key facts

  • EPIC
    ATXI
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US05360L4032
  • Market cap
    $2.61m
  • Employees
    2
  • Shares in issue
    3.18m
  • Exchange
    Over The Counter
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.